Herantis Pharma

Herantis Pharma Plc

Company release 9 June 2023 at EEST

Herantis Pharma Oyj - Managers' Transactions

____________________________________________

Person subject to the notification requirement

Name: Antti Vuolanto

Position: Chief Executive Officer

 Issuer: Herantis Pharma Oyj

LEI: 743700W4CQVYAT3WKK38

Notification type: INITIAL NOTIFICATION

Reference number: 33224/5/8

____________________________________________

Transaction date: 2023-06-09

Outside a trading venue

Instrument type: FINANCIAL INSTRUMENT LINKED TO A SHARE OR A DEBT INSTRUMENT

Name of the instrument: 2023 option rights in Herantis Pharma Plc

Nature of transaction: ACCEPTANCE OF A STOCK OPTION

Transaction details

(1): Volume: 165000 Unit price: 0 EUR

Aggregated transactions (1):

Volume: 165000 Volume weighted average price: 0 EUR

____________________________________________

Further information:

Julie Silber/Gabriela Urquilla

Tel: +46 (0)7 93 486 277/+46 (0)72-396 72 19

Email:ir@herantis.com

Certified Advisor: UB Securities Ltd, +358 9 25 380 225

Company website: www.herantis.com

Distribution:

Main media
www.herantis.com